KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Net Income (2016 - 2025)

Historic Net Income for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to $2.6 billion.

  • Astrazeneca's Net Income rose 5780.31% to $2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.4 billion, marking a year-over-year increase of 4269.93%. This contributed to the annual value of $12.4 billion for FY2025, which is 4269.93% up from last year.
  • As of Q4 2025, Astrazeneca's Net Income stood at $2.6 billion, which was up 5780.31% from $3.2 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Net Income ranged from a high of $3.4 billion in Q1 2025 and a low of -$2.0 billion during Q3 2021
  • Moreover, its 5-year median value for Net Income was $1.7 billion (2023), whereas its average is $1.5 billion.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 33458.38% in 2021, then soared by 74534.41% in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's Net Income stood at -$636.0 million in 2021, then skyrocketed by 222.33% to $778.0 million in 2022, then increased by 15.3% to $897.0 million in 2023, then surged by 85.73% to $1.7 billion in 2024, then skyrocketed by 57.8% to $2.6 billion in 2025.
  • Its last three reported values are $2.6 billion in Q4 2025, $3.2 billion for Q3 2025, and $3.1 billion during Q2 2025.